Literature DB >> 34243870

Management of Anaplastic and Recurrent Differentiated Thyroid Cancer: Indications for Surgical Resection, Molecular Testing, and Systemic Therapy.

Maria E Cabanillas1, Salmaan Ahmed2, Jennifer Rui Wang3.   

Abstract

Differentiated and anaplastic thyroid cancer are tumors derived from follicular thyroid cancers and are clinically and genetically distinct. Treatment of these tumors has evolved over the past decade, with 6 drugs/drug combinations that are US Food and Drug Administration approved.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; Kinase inhibitor; MEK; NTRK; RET

Year:  2021        PMID： 34243870     DOI： 10.1016/j.nic.2021.04.005

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN： 1052-5149            Impact factor:   2.264


  3 in total

1.  A New Way Out of the Predicament of Anaplastic Thyroid Carcinoma From Existing Data Analysis.

Authors:  Yikun Zhou; Yang Zhao; Xi Ding; Jing Liang; Huayang Xu; Yuxuan Lin; Hamad Haider Khan; Bingyin Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

2.  Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients.

Authors:  Xun Weng; Yujiao Cai
Journal:  Dis Markers       Date:  2022-01-31       Impact factor: 3.434

3.  Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.

Authors:  Cristina Luongo; Tommaso Porcelli; Francesca Sessa; Maria Angela De Stefano; Francesco Scavuzzo; Vincenzo Damiano; Michele Klain; Claudio Bellevicine; Elide Matano; Giancarlo Troncone; Martin Schlumberger; Domenico Salvatore
Journal:  Curr Oncol       Date:  2021-12-16       Impact factor: 3.677
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.